117 related articles for article (PubMed ID: 21456072)
1. Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer.
Almasi CE; Brasso K; Iversen P; Pappot H; Høyer-Hansen G; Danø K; Christensen IJ
Prostate; 2011 Jun; 71(8):899-907. PubMed ID: 21456072
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of circulating intact and cleaved forms of urokinase plasminogen activator receptor in inoperable chemotherapy treated cholangiocarcinoma patients.
Grunnet M; Christensen IJ; Lassen U; Jensen LH; Lydolph M; Lund IK; Thurison T; Høyer-Hansen G; Mau-Sørensen M
Clin Biochem; 2014 May; 47(7-8):599-604. PubMed ID: 24530340
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients.
Lomholt AF; Christensen IJ; Høyer-Hansen G; Nielsen HJ
Acta Oncol; 2010 Aug; 49(6):805-11. PubMed ID: 20524776
[TBL] [Abstract][Full Text] [Related]
4. The liberated domain I of urokinase plasminogen activator receptor--a new tumour marker in small cell lung cancer.
Almasi CE; Drivsholm L; Pappot H; Høyer-Hansen G; Christensen IJ
APMIS; 2013 Mar; 121(3):189-96. PubMed ID: 23030781
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of urokinase plasminogen activator receptor and its cleaved forms in blood from patients with non-small cell lung cancer.
Almasi CE; Høyer-Hansen G; Christensen IJ; Pappot H
APMIS; 2009 Oct; 117(10):755-61. PubMed ID: 19775344
[TBL] [Abstract][Full Text] [Related]
6. Urokinase receptor forms in serum from non-small cell lung cancer patients: relation to prognosis.
Almasi CE; Christensen IJ; Høyer-Hansen G; Danø K; Pappot H; Dienemann H; Muley T
Lung Cancer; 2011 Dec; 74(3):510-5. PubMed ID: 21640427
[TBL] [Abstract][Full Text] [Related]
7. Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab.
Tarpgaard LS; Christensen IJ; Høyer-Hansen G; Lund IK; Guren TK; Glimelius B; Sorbye H; Tveit KM; Nielsen HJ; Moreira JM; Pfeiffer P; Brünner N
Int J Cancer; 2015 Nov; 137(10):2470-7. PubMed ID: 25664394
[TBL] [Abstract][Full Text] [Related]
8. Specific immunoassays for detection of intact and cleaved forms of the urokinase receptor.
Piironen T; Laursen B; Pass J; List K; Gårdsvoll H; Ploug M; Danø K; Høyer-Hansen G
Clin Chem; 2004 Nov; 50(11):2059-68. PubMed ID: 15345662
[TBL] [Abstract][Full Text] [Related]
9. Plasma levels of intact and cleaved urokinase plasminogen activator receptor (uPAR) in men with clinically localised prostate cancer.
Kristensen G; Berg KD; Lippert S; Christensen IJ; Brasso K; Høyer-Hansen G; Røder MA
J Clin Pathol; 2017 Dec; 70(12):1063-1068. PubMed ID: 28607123
[TBL] [Abstract][Full Text] [Related]
10. Copenhagen uPAR prostate cancer (CuPCa) database: protocol and early results.
Lippert S; Berg KD; Høyer-Hansen G; Lund IK; Iversen P; Christensen IJ; Brasso K; Røder MA
Biomark Med; 2016; 10(2):209-16. PubMed ID: 26764285
[TBL] [Abstract][Full Text] [Related]
11. Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum.
Piironen T; Haese A; Huland H; Steuber T; Christensen IJ; Brünner N; Danø K; Høyer-Hansen G; Lilja H
Clin Chem; 2006 May; 52(5):838-44. PubMed ID: 16543389
[TBL] [Abstract][Full Text] [Related]
12. Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer.
Henic E; Borgfeldt C; Christensen IJ; Casslén B; Høyer-Hansen G
Clin Cancer Res; 2008 Sep; 14(18):5785-93. PubMed ID: 18794088
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.
Pedersen H; Brünner N; Francis D; Osterlind K; Rønne E; Hansen HH; Danø K; Grøndahl-Hansen J
Cancer Res; 1994 Sep; 54(17):4671-5. PubMed ID: 8062262
[TBL] [Abstract][Full Text] [Related]
14. A new assay for measurement of the liberated domain I of the urokinase receptor in plasma improves the prediction of survival in colorectal cancer.
Thurison T; Lomholt AF; Rasch MG; Lund IK; Nielsen HJ; Christensen IJ; Høyer-Hansen G
Clin Chem; 2010 Oct; 56(10):1636-40. PubMed ID: 20802096
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of time to prostate-specific antigen (PSA) nadir and its relationship to survival beyond time to PSA nadir for prostate cancer patients with bone metastases after primary androgen deprivation therapy.
Teoh JY; Tsu JH; Yuen SK; Chan SY; Chiu PK; Lee WM; Wong KW; Ho KL; Hou SS; Ng CF; Yiu MK
Ann Surg Oncol; 2015 Apr; 22(4):1385-91. PubMed ID: 25234025
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
Grøndahl-Hansen J; Christensen IJ; Briand P; Pappot H; Mouridsen HT; Blichert-Toft M; Danø K; Brünner N
Clin Cancer Res; 1997 Feb; 3(2):233-9. PubMed ID: 9815678
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue.
Almasi CE; Høyer-Hansen G; Christensen IJ; Danø K; Pappot H
Lung Cancer; 2005 Jun; 48(3):349-55. PubMed ID: 15893003
[TBL] [Abstract][Full Text] [Related]
18. The concentration of the cleaved suPAR forms in pre- and postoperative plasma samples improves the prediction of survival in colorectal cancer: A nationwide multicenter validation and discovery study.
Rolff HC; Christensen IJ; Svendsen LB; Wilhelmsen M; Lund IK; Thurison T; Høyer-Hansen G; Illemann M; Nielsen HJ;
J Surg Oncol; 2019 Dec; 120(8):1404-1411. PubMed ID: 31646652
[TBL] [Abstract][Full Text] [Related]
19. Circulating intact and cleaved forms of the urokinase-type plasminogen activator receptor: biological variation, reference intervals and clinical useful cut-points.
Thurison T; Christensen IJ; Lund IK; Nielsen HJ; Høyer-Hansen G
Clin Chim Acta; 2015 Jan; 439():84-90. PubMed ID: 25305537
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients.
Gupta A; Lotan Y; Ashfaq R; Roehrborn CG; Raj GV; Aragaki CC; Montorsi F; Shariat SF
Eur Urol; 2009 May; 55(5):1124-33. PubMed ID: 18585843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
